ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Heterogeneity of cancer-associated fibroblast subtypes in the prostate cancer microenvironment and their clinical implications: prognostic model construction and therapeutic target exploration based on bioinformatics analysis.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundIn prostate cancer (PCa), cancer-associated fibroblasts (CAFs) play a pivotal role, yet their specific mechanisms remain incompletely elucidated.
methodsThis study analyzed transcriptomic data and clinical information from 948 PCa patients sourced from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Three distinct CAF subtypes (C1, C2, C3) were identified, and their roles in tumor progression and the immune microenvironment were explored.
resultsThe results demonstrated significant associations between these CAF subtypes and patient prognosis, tumor microenvironment (TME) characteristics, as well as immune cell infiltration. Notably, the C2 subtype exhibited the strongest immune infiltration capacity and highest expression of CAF-related genes, correlating with poor prognosis and marked features of immune evasion. In-depth analysis revealed that the C2 subtype might promote tumor progression by enhancing immune cell infiltration and regulating immune checkpoint expression. Based on differential gene analysis, a risk score model was constructed. It was found that the COL1A1 gene was highly expressed in the high-risk group and was closely associated with immune cell infiltration and immune checkpoint expression.
conclusionHigh expression of COL1A1 was significantly correlated with poor prognosis in PCa patients, and its interaction with HAVCR2 may represent a potential therapeutic target. This study provides novel insights into the role of CAF subtypes within the PCa immune microenvironment, highlighting the potential of COL1A1 as both a biomarker and a therapeutic target, which may offer new directions for PCa treatment strategies.
Indexed as
Identifiers
42322557What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.